Cargando…

Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis

To determine the role of the cysteine proteinase inhibitor cystatin C in the invasive behavior of squamous cell carcinoma of the head and neck (SCCHN), Cystatin C protein level was measured in 82 pairs of primary tumour tissue and adjacent noncancerous mucosa, using the enzyme-linked immunosorbent a...

Descripción completa

Detalles Bibliográficos
Autores principales: Strojan, P, Oblak, I, Svetic, B, Šmid, L, Kos, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409457/
https://www.ncbi.nlm.nih.gov/pubmed/15138478
http://dx.doi.org/10.1038/sj.bjc.6601830
_version_ 1782155768829575168
author Strojan, P
Oblak, I
Svetic, B
Šmid, L
Kos, J
author_facet Strojan, P
Oblak, I
Svetic, B
Šmid, L
Kos, J
author_sort Strojan, P
collection PubMed
description To determine the role of the cysteine proteinase inhibitor cystatin C in the invasive behavior of squamous cell carcinoma of the head and neck (SCCHN), Cystatin C protein level was measured in 82 pairs of primary tumour tissue and adjacent noncancerous mucosa, using the enzyme-linked immunosorbent assay. The median level of cystatin C in tumour tissue was 1.18 times lower than that in corresponding mucosa (P=0.031). In normal mucosa samples, the cystatin C level was influenced by the site of sampling: it was lower in nonlaryngeal tissue samples (oral cavity, oro- or hypopharynx) than in laryngeal samples (P=0.004). The tumour cystatin C level correlated inversely with pN-stage (P=0.047), whereas a trend of lower cystatin C levels was observed in the group with extranodal tumour extension compared to those with no extranodal spread (P=0.069). In univariate analysis, the patients with low tumour cystatin C levels exhibited poor disease-free survival (DFS, P=0.013) and disease-specific survival (DSS, P=0.013). In multivariate analysis, the most powerful predictor of survival was pN-stage (DFS: P=0.040, HR 2.78; DSS: P=0.011, HR 4.36,), followed by the cystatin C level (DFS: P=0.043, HR 0.22; DSS: P=0.067, HR 0.25). When comparing the prognostic strength of cystatin C to that of stefin A, another cysteine proteinase inhibitor, which emerged as the most significant prognosticator for survival in our previous study analysing the same cohort of patients, stefin A proved to be significantly more reliable predictor for both DFS and DSS than cystatin C. Our results indicate that cystatin C is implicated in the invasive behavior of SCCHN, and that there are variations in regulation of proteolytic pathways under nonmalignant conditions, inherent to individual subsites inside the upper aerodigestive tract. The correlation between high cystatin C levels and improved survival concurs with the concept of the protective role of high levels of cysteine proteinase inhibitors in tissue homogenates that has been previously suggested by the survival results in breast and lung carcinoma as well as SCCHN.
format Text
id pubmed-2409457
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24094572009-09-10 Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis Strojan, P Oblak, I Svetic, B Šmid, L Kos, J Br J Cancer Molecular and Cellular Pathology To determine the role of the cysteine proteinase inhibitor cystatin C in the invasive behavior of squamous cell carcinoma of the head and neck (SCCHN), Cystatin C protein level was measured in 82 pairs of primary tumour tissue and adjacent noncancerous mucosa, using the enzyme-linked immunosorbent assay. The median level of cystatin C in tumour tissue was 1.18 times lower than that in corresponding mucosa (P=0.031). In normal mucosa samples, the cystatin C level was influenced by the site of sampling: it was lower in nonlaryngeal tissue samples (oral cavity, oro- or hypopharynx) than in laryngeal samples (P=0.004). The tumour cystatin C level correlated inversely with pN-stage (P=0.047), whereas a trend of lower cystatin C levels was observed in the group with extranodal tumour extension compared to those with no extranodal spread (P=0.069). In univariate analysis, the patients with low tumour cystatin C levels exhibited poor disease-free survival (DFS, P=0.013) and disease-specific survival (DSS, P=0.013). In multivariate analysis, the most powerful predictor of survival was pN-stage (DFS: P=0.040, HR 2.78; DSS: P=0.011, HR 4.36,), followed by the cystatin C level (DFS: P=0.043, HR 0.22; DSS: P=0.067, HR 0.25). When comparing the prognostic strength of cystatin C to that of stefin A, another cysteine proteinase inhibitor, which emerged as the most significant prognosticator for survival in our previous study analysing the same cohort of patients, stefin A proved to be significantly more reliable predictor for both DFS and DSS than cystatin C. Our results indicate that cystatin C is implicated in the invasive behavior of SCCHN, and that there are variations in regulation of proteolytic pathways under nonmalignant conditions, inherent to individual subsites inside the upper aerodigestive tract. The correlation between high cystatin C levels and improved survival concurs with the concept of the protective role of high levels of cysteine proteinase inhibitors in tissue homogenates that has been previously suggested by the survival results in breast and lung carcinoma as well as SCCHN. Nature Publishing Group 2004-05-17 2004-04-27 /pmc/articles/PMC2409457/ /pubmed/15138478 http://dx.doi.org/10.1038/sj.bjc.6601830 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Strojan, P
Oblak, I
Svetic, B
Šmid, L
Kos, J
Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis
title Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis
title_full Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis
title_fullStr Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis
title_full_unstemmed Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis
title_short Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis
title_sort cysteine proteinase inhibitor cystatin c in squamous cell carcinoma of the head and neck: relation to prognosis
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409457/
https://www.ncbi.nlm.nih.gov/pubmed/15138478
http://dx.doi.org/10.1038/sj.bjc.6601830
work_keys_str_mv AT strojanp cysteineproteinaseinhibitorcystatincinsquamouscellcarcinomaoftheheadandneckrelationtoprognosis
AT oblaki cysteineproteinaseinhibitorcystatincinsquamouscellcarcinomaoftheheadandneckrelationtoprognosis
AT sveticb cysteineproteinaseinhibitorcystatincinsquamouscellcarcinomaoftheheadandneckrelationtoprognosis
AT smidl cysteineproteinaseinhibitorcystatincinsquamouscellcarcinomaoftheheadandneckrelationtoprognosis
AT kosj cysteineproteinaseinhibitorcystatincinsquamouscellcarcinomaoftheheadandneckrelationtoprognosis